LLY

981.86

-0.29%↓

JNJ

243.2

+0.67%↑

ABBV

221.94

+1.03%↑

NVS

154.64

+1.01%↑

AZN

192.02

+1%↑

LLY

981.86

-0.29%↓

JNJ

243.2

+0.67%↑

ABBV

221.94

+1.03%↑

NVS

154.64

+1.01%↑

AZN

192.02

+1%↑

LLY

981.86

-0.29%↓

JNJ

243.2

+0.67%↑

ABBV

221.94

+1.03%↑

NVS

154.64

+1.01%↑

AZN

192.02

+1%↑

LLY

981.86

-0.29%↓

JNJ

243.2

+0.67%↑

ABBV

221.94

+1.03%↑

NVS

154.64

+1.01%↑

AZN

192.02

+1%↑

LLY

981.86

-0.29%↓

JNJ

243.2

+0.67%↑

ABBV

221.94

+1.03%↑

NVS

154.64

+1.01%↑

AZN

192.02

+1%↑

Search

Simulations Plus Inc

Abrir

SetorSaúde

12.19 -1.85

Visão Geral

Variação de preço das ações

24h

Atual

Mín

12.03

Máximo

12.52

Indicadores-chave

By Trading Economics

Rendimento

1.4M

676K

Vendas

961K

18M

Rendimento de Dividendos

0.48

Margem de lucro

3.67

Funcionários

212

EBITDA

-3M

2.3M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+52.73% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.48%

2.40%

Próximos Ganhos

2 de abr. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-118M

250M

Abertura anterior

14.04

Fecho anterior

12.19

Sentimento de Notícias

By Acuity

50%

50%

133 / 351 Ranking em Healthcare

Simulations Plus Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de mar. de 2026, 21:14 UTC

Notícias Principais

Week Ahead for FX, Bonds: Central Bank Decisions -2-

15 de mar. de 2026, 21:14 UTC

Notícias Principais

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

16 de mar. de 2026, 00:00 UTC

Notícias Principais

Hack on U.S. Medical Company Shows Reach of Iran's Cyber Capabilities -- WSJ

15 de mar. de 2026, 23:45 UTC

Conversa de Mercado

Nikkei May Decline on Concerns About Prolonged Middle East Conflict -- Market Talk

15 de mar. de 2026, 23:44 UTC

Conversa de Mercado
Notícias Principais

Gold Falls as Rising Energy Prices Exacerbate Inflation Worries -- Market Talk

15 de mar. de 2026, 23:35 UTC

Conversa de Mercado
Notícias Principais

Oil Futures Rise on Supply Disruption Concerns -- Market Talk

15 de mar. de 2026, 23:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Micron Completes Acquisition Of PSMC's Tongluo P5 Site In Taiwan >MU

15 de mar. de 2026, 22:37 UTC

Conversa de Mercado

March Rate Hike Would Distance RBA From Government's May Budget -- Market Talk

15 de mar. de 2026, 22:18 UTC

Conversa de Mercado

RBA's Likely Hike Motivated By Inflation, Not Middle East -- Market Talk

15 de mar. de 2026, 22:14 UTC

Ganhos

Genscript Biotech 2025 Adj Net $230.35M Vs. Adj Net $59.83M>1548.HK

15 de mar. de 2026, 22:14 UTC

Ganhos

Genscript Biotech: 2025 Loss Due to High Base Effect, One-off Unrealized Gains Seen Last Year >1548.HK

15 de mar. de 2026, 22:14 UTC

Ganhos

Genscript Biotech 2025 Rev $959.53M Vs. $594.49M >1548.HK

15 de mar. de 2026, 22:14 UTC

Ganhos

Genscript Biotech 2025 Loss $532.83M Vs. Net $2.96B >1548.HK

15 de mar. de 2026, 22:14 UTC

Ganhos

Genscript Biotech: 2025 Rev Supported by Substantial Increase in License Revenue>1548.HK

15 de mar. de 2026, 22:00 UTC

Notícias Principais

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15 de mar. de 2026, 22:00 UTC

Notícias Principais

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15 de mar. de 2026, 03:00 UTC

Notícias Principais

For Xi, Iran War Reinforces View of U.S. as Dangerous Superpower -- WSJ

14 de mar. de 2026, 15:00 UTC

Notícias Principais

Iran War Delivers Windfall to America's Oil Country -- WSJ

14 de mar. de 2026, 02:03 UTC

Ganhos

This Copper Stock Is Worth Mining for Profits -- Barrons.com

14 de mar. de 2026, 01:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

14 de mar. de 2026, 00:29 UTC

Aquisições, Fusões, Aquisições de Empresas

13D Filings -- Barrons.com

13 de mar. de 2026, 22:27 UTC

Conversa de Mercado
Notícias Principais

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

13 de mar. de 2026, 22:13 UTC

Conversa de Mercado
Notícias Principais

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

13 de mar. de 2026, 22:04 UTC

Conversa de Mercado
Notícias Principais

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

13 de mar. de 2026, 22:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

13 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

13 de mar. de 2026, 20:50 UTC

Conversa de Mercado
Notícias Principais

Financial Services Roundup: Market Talk

13 de mar. de 2026, 20:02 UTC

Conversa de Mercado

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

13 de mar. de 2026, 19:50 UTC

Conversa de Mercado
Notícias Principais

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

13 de mar. de 2026, 19:35 UTC

Notícias Principais

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

Comparação entre Pares

Variação de preço

Simulations Plus Inc Previsão

Preço-alvo

By TipRanks

52.73% parte superior

Previsão para 12 meses

Média 19 USD  52.73%

Máximo 19 USD

Mínimo 19 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Simulations Plus Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

4 ratings

2

Comprar

2

Manter

0

Vender

Sentimento

By Acuity

133 / 351 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat